SEMATERUI Semaglutide Injection in vial 3ml/4mg

Semaglutide Injection (3ml/4mg, SEMATERUI) – Product Information

This product is shipped via SF Express cold-chain logistics. It is shipped exclusively via SF Express with "freight collect" terms; the shipping fee (approximately 25 RMB) must be paid directly to the courier upon delivery.

【Basic Product Information】

Generic Name: Semaglutide Injection

Brand Name: SEMATERUI / Ozempic

Appearance: Clear, colorless or almost colorless liquid; pH = 7.4.

Specification: 4mg/3ml (pre-filled injection pen); contains 1.34mg of semaglutide per milliliter.

At a dosage of 0.25mg per injection, the pen provides 16 doses; at 0.5mg per injection, it provides 8 doses.

Please purchase compatible needles from a local pharmacy based on skin thickness requirements.

Storage: Store refrigerated at 2°C–8°C; do not freeze. Unopened (unused) pens must be stored in the refrigerator (2°C–8°C) and protected from freezing. Opened (in-use) pens may continue to be stored in the refrigerator (2°C–8°C) or kept at room temperature (not exceeding 30°C).

Manufacturer: Protech Telelinks

【Indications】

1. Blood Glucose Control

Mechanism: Mimics GLP-1 receptor activity to stimulate insulin secretion (glucose-dependent) and inhibit glucagon release, thereby lowering fasting and postprandial blood glucose levels.

Target Population: Patients with Type 2 diabetes (specifically those with inadequate glycemic control despite treatment with metformin or sulfonylureas).

Efficacy: Significantly improves glycated hemoglobin (HbA1c) levels and reduces blood glucose fluctuations.

2. Weight Management

Mechanism: Delays gastric emptying, increases satiety, and suppresses appetite via the central nervous system to reduce food intake.

Efficacy: Long-term use can result in a weight loss of approximately 5%–15% (in diabetic patients) or 10%–15% (in obese individuals). Target Population:

Adults with a BMI ≥30 (obesity) or a BMI ≥27 accompanied by metabolic diseases (e.g., hypertension, diabetes).

3. Cardiovascular Protection

Mechanism: Improves vascular endothelial function, reduces the release of inflammatory factors, and modulates the stability of atherosclerotic plaques.

Effect: Reduces the risk of major adverse cardiovascular events (e.g., myocardial infarction, stroke) by approximately 26% in patients with type 2 diabetes.

Update Note: New clinical evidence added in April 2025 confirms that the weight-loss version (Nuoheying®) also provides cardiovascular protection.

4. Other Metabolic Regulatory Effects

Lipid Regulation: Lowers triglycerides and low-density lipoprotein cholesterol (LDL-C); improves dyslipidemia.

Renal Protection: Reduces urinary protein excretion and slows the decline in glomerular filtration rate; may offer protective effects against diabetic nephropathy.

Potential Neuroprotection: Animal studies suggest it may delay the progression of neurodegenerative diseases via anti-inflammatory and antioxidant pathways, though evidence in humans remains insufficient.

[Dosage and Administration]

1. Starting Dose and Adjustment

Starting Dose: 0.25 mg via subcutaneous injection once weekly for 4 weeks to minimize the risk of gastrointestinal adverse reactions.

Dose Adjustment:

Increase to 0.5 mg/week after 4 weeks; if blood glucose or weight control is suboptimal, the dose may be further adjusted to 1 mg/week (with a minimum interval of 4 weeks between adjustments).

Maximum Recommended Dose: Does not exceed 1 mg/week for either diabetes treatment or weight loss; adjustments in special circumstances require physician assessment.

2. Injection Method and Requirements

Injection Site: Subcutaneous adipose tissue of the abdomen, thigh, or upper arm; rotate sites weekly to minimize local irritation.

Injection Timing:

Inject on the same day each week; no adjustment based on meal times is required.

If the day needs to be changed, ensure an interval of ≥48 hours between doses.

3. Management of Missed Doses

If a dose is missed by ≤5 days, administer it immediately; if missed by >5 days, skip the dose and resume the schedule the following week.

Do not administer a double dose within the same week. 4. Precautions

Contraindications: Use is prohibited in patients with a history of medullary thyroid carcinoma (MTC) or pancreatitis.

Side Effect Monitoring: Common gastrointestinal reactions include nausea and diarrhea (usually resolving in the short term); regular follow-up visits are required.

Combined Interventions: Dietary control and regular exercise should be combined with the medication to optimize therapeutic efficacy.

[Adverse Reactions]

Common: Nausea, vomiting, diarrhea, decreased appetite;

Serious: Hypoglycemia (when used with sulfonylureas or insulin), worsening of diabetic retinopathy;

Rare: Acute pancreatitis (requires immediate discontinuation of the drug).

[Contraindications]

Personal or family history of medullary thyroid carcinoma (MTC);

Patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2);

Hypersensitivity to semaglutide or any excipients.

[Precautions]

Special Populations:

Pregnant/Breastfeeding Women: Use prohibited (lack of safety data);

Hepatic/Renal Impairment: Use with caution in patients with moderate-to-severe hepatic impairment or end-stage renal disease.

Drug Interactions:

Monitor for risk of hypoglycemia when used with oral antidiabetic drugs;

Avoid concomitant use with other GLP-1 receptor agonists or weight-loss medications.

Long-term Use: Regularly monitor blood glucose, hepatic and renal function, and signs of retinopathy.

[Instructions for Injection Device]

Operation of Pre-filled Pen

Check that the liquid is clear before injection; avoid shaking;

Align the dose selector precisely with the scale markings;

Keep the needle inserted for 6 seconds after injection to ensure the full dose is delivered.

[Storage Instructions]

I. Unopened (Unused) Semaglutide Injection

Storage Temperature: Store in a refrigerator at 2°C–8°C; do not freeze.

Reason: Low-temperature storage maintains the stability of the active ingredients, preventing degradation or denaturation.

Prohibition: Freezing causes the solution to solidify and may damage the drug's structure; using frozen medication may render it ineffective or even increase the risk of adverse reactions.

Placement: Avoid direct contact between the medication and the refrigerator walls or cooling elements to prevent exposure to excessively low local temperatures. It can be placed on the inside of the refrigerator door or in a dedicated storage compartment (where the temperature is relatively stable).

Protect from light: The medication must be kept in its original packaging and shielded from direct sunlight or intense light to prevent the active ingredients from degrading due to photo-oxidation.

II. Opened (currently in use) Semaglutide injection

Storage conditions:

After opening, it may be stored in a refrigerator at 2°C–8°C or at room temperature not exceeding 30°C, subject to the following time limits:

If stored in a refrigerator: It can be used up to the expiration date indicated on the label (usually around 1 month).

If stored at room temperature: It is generally recommended to use it within 30 days of opening (please refer to the "in-use shelf life" specified in the package insert).

Note: When storing at room temperature, avoid high temperatures and humid environments (such as bathrooms or windowsills exposed to direct sunlight) and keep away from heat sources (such as radiators or areas near microwaves).

Managing the usage period:

After opening, it is recommended to mark the "date opened" and "expiration date" on the vial to clearly track the usage period and avoid using expired medication.

Note: This product must be used strictly according to medical advice; do not self-adjust the dosage or indications (e.g., using it for weight loss when not indicated).

Specifications

Product Name: Semaglutide Injection 3ml/4mg (1.34mg/ml) (16-dose pen)

Common Name: Semaglutide Injection

Active Ingredient: Semaglutide

Dosage Form: Injection

Specification: 3ml/4mg (1.34mg/ml)

Manufacturer: Protech Telelinks

Indication: 1. Blood glucose control

Mechanism: Mimics GLP-1 receptor activity to stimulate insulin secretion (glucose-dependent) and inhibit glucagon release, thereby lowering fasting and postprandial blood glucose levels.

Target Population: Patients with Type 2 diabetes (specifically those with inadequate glycemic control despite combination therapy with metformin or sulfonylureas).

Effect: Significantly improves glycated hemoglobin (HbA1c) levels and reduces blood glucose fluctuations. 2. Weight Management

Mechanism: Slows gastric emptying, increases satiety, and suppresses appetite via the central nervous system, thereby reducing food intake.

Effect: Long-term use can lead to a weight loss of approximately 5%–15% (in patients with diabetes) or 10%–15% (in individuals with obesity).

Target Population:

Adults with a BMI ≥30 (obesity) or a BMI ≥27 accompanied by metabolic diseases (e.g., hypertension, diabetes).

3. Cardiovascular Protection

Mechanism: Improves vascular endothelial function, reduces the release of inflammatory factors, and modulates the stability of atherosclerotic plaques.

Effect: Reduces the risk of major adverse cardiovascular events (e.g., myocardial infarction, stroke) by approximately 26% in patients with type 2 diabetes.

Update Note: Clinical evidence added in April 2025 confirms that the weight-loss version (NovoYing®) also provides cardiovascular protection.

4. Other Metabolic Regulatory Effects

Lipid Regulation: Lowers triglycerides and low-density lipoprotein cholesterol (LDL-C); improves dyslipidemia.

Renal Protection: Reduces urinary protein excretion and slows the decline of the glomerular filtration rate (GFR); may offer protective effects against diabetic nephropathy.

Potential Neuroprotection: Animal studies suggest it may delay the progression of neurodegenerative diseases through anti-inflammatory and antioxidant pathways, though evidence in humans remains insufficient.

Dosage and Administration: 1. Starting Dose and Adjustment

Starting Dose: 0.25 mg via subcutaneous injection once weekly for 4 weeks to minimize the risk of gastrointestinal adverse reactions.

Dose Adjustment:

Increase to 0.5 mg/week after 4 weeks; if blood glucose or weight control is suboptimal, the dose may be further adjusted to 1 mg/week (with a minimum interval of 4 weeks between adjustments).

Maximum Recommended Dose: Does not exceed 1 mg/week for either diabetes treatment or weight management; adjustments in special circumstances require physician assessment.

2. Injection Method and Requirements

Injection Site: Subcutaneous adipose tissue of the abdomen, thigh, or upper arm; rotate sites weekly to minimize local irritation.

Injection Timing:

Administer on the same day each week; no adjustment based on meal times is required. If rescheduling is necessary, ensure an interval of at least 48 hours between doses.

3. Handling missed doses

If a dose is missed by 5 days or less, administer it immediately; if the delay exceeds 5 days, skip the missed dose and resume the schedule the following week.

Do not administer a double dose within the same week.

4. Precautions

Contraindications: Use is prohibited in patients with a history of medullary thyroid carcinoma or pancreatitis.

Side effect monitoring: Common gastrointestinal reactions include nausea and diarrhea (usually transient); regular follow-up visits are required.

Combined interventions: Dietary control and regular exercise are necessary to optimize therapeutic efficacy.